The HER2-positive rate of papillary adenocarcinomas was especially high in gastric cancer (62%, 8/13, p = 0.023) (Oono et al., 2018) and lung cancer (17%, 7/41, p = 0.029) (Kim et al., 2017). Here, ERBB2 is linked to lung carcinoma.